Digestive Disease Interventions 2021; 05(04): 307-310
DOI: 10.1055/s-0041-1733796
Review Article

Percutaneous Transhepatic Biodegradable Biliary Stent Placement for Benign Biliary Strictures

1   Division of Vascular and Interventional Radiology, Department of Medical Imaging, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2   Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia
,
1   Division of Vascular and Interventional Radiology, Department of Medical Imaging, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2   Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia
,
Khalid Almasar
1   Division of Vascular and Interventional Radiology, Department of Medical Imaging, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2   Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia
,
Bayan AlBdah
2   Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia
3   Department of Biostatics and Bioinformatics, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
,
Refaat Salman
1   Division of Vascular and Interventional Radiology, Department of Medical Imaging, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
2   Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia
› Author Affiliations

Abstract

This article aimed to assess the safety and effectiveness of biodegradable stents in the management of benign biliary strictures. This is a retrospective observational study that included all adult patients who had biodegradable stent placement for a benign cause of biliary stricture between July 2016 and August 2019. Nineteen patients were included. Seventeen patients had liver transplant. One patient had hepaticojejunostomy due to primary sclerosing cholangitis and one patient had iatrogenic left main bile duct occlusion. Stents were successfully deployed in all 19 patients (technical success: 100%). Patency rate was 90% (17/19) at 6 months and 80% (12/15) at 12 months. Seven patients in the study had stricture recurrence and needed reintervention with mean time to reintervention of 418 days (range: 8–1,155 days). There was one major complication due to cholangitis and sepsis, which required a treatment course with piperacillin/tazobactam for 10 days. No procedure-related pancreatitis or deaths occurred. Biodegradable stents are a safe and effective treatment option for benign biliary strictures and can achieve long-term patency without the need for reinterventions.



Publication History

Received: 20 March 2021

Accepted: 24 June 2021

Article published online:
26 July 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Kapoor BS, Mauri G, Lorenz JM. Management of biliary strictures: state-of-the-art review. Radiology 2018; 289 (03) 590-603
  • 2 Almeida GG, Donato P. Biodegradable versus multiple plastic stent implantation in benign biliary strictures: a systematic review and meta-analysis. Eur J Radiol 2020; 125: 108899
  • 3 Siiki A, Sand J, Laukkarinen J. A systematic review of biodegradable biliary stents: promising biocompatibility without stent removal. Eur J Gastroenterol Hepatol 2018; 30 (08) 813-818
  • 4 Mauri G, Michelozzi C, Melchiorre F. et al. Benign biliary strictures refractory to standard bilioplasty treated using polydoxanone biodegradable biliary stents: retrospective multicentric data analysis on 107 patients. Eur Radiol 2016; 26 (11) 4057-4063
  • 5 Arabi M, Alrehaili B, Salman R. et al. Percutaneous transhepatic biodegradable stent placement for benign anastomotic biliary strictures: short-term outcomes of a single-institution experience. Arab J Intervent Radiol 2019; 3: 19-22
  • 6 Khalilzadeh O, Baerlocher MO, Shyn PB. et al. Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol 2017; 28 (10) 1432-1437.e3 [erratum in J Vasc Interv Radiol 2018;29(1):146]
  • 7 Fuccio L, Hassan C, Frazzoni L, Miglio R, Repici A. Clinical outcomes following stent placement in refractory benign esophageal stricture: a systematic review and meta-analysis. Endoscopy 2016; 48 (02) 141-148
  • 8 Lorenzo-Zúñiga V, Moreno-de-Vega V, Marín I, Boix J. Biodegradable stents in gastrointestinal endoscopy. World J Gastroenterol 2014; 20 (09) 2212-2217
  • 9 Stehlik L, Hytych V, Letackova J, Kubena P, Vasakova M. Biodegradable polydioxanone stents in the treatment of adult patients with tracheal narrowing. BMC Pulm Med 2015; 15: 164
  • 10 Battistel M, Senzolo M, Ferrarese A. et al. Biodegradable biliary stents for percutaneous treatment of post-liver transplantation refractory benign biliary anastomotic strictures. Cardiovasc Intervent Radiol 2020; 43 (05) 749-755
  • 11 De Gregorio MA, Criado E, Guirola JA. et al; Spanish Group BiELLA (SERVEI). Absorbable stents for treatment of benign biliary strictures: long-term follow-up in the prospective Spanish registry. Eur Radiol 2020; 30 (08) 4486-4495